These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27339303)

  • 21. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial.
    Power-Hays A; Namazzi R; Kato C; McElhinney KE; Conroy AL; Hume H; John C; O'Hara SM; Stuber SE; Lane A; Latham TS; Opoka RO; Ware RE
    Acta Haematol; 2024 Jun; ():1-12. PubMed ID: 38824918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methemoglobin and nitric oxide therapy in Ugandan children hospitalized for febrile illness: results from a prospective cohort study and randomized double-blind placebo-controlled trial.
    Conroy AL; Hawkes M; Hayford K; Hermann L; McDonald CR; Sharma S; Namasopo S; Opoka RO; John CC; Liles WC; Miller C; Kain KC
    BMC Pediatr; 2016 Nov; 16(1):177. PubMed ID: 27814710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola.
    Chambers TM; Kahan S; Camanda JF; Scheurer M; Airewele GE
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27365. PubMed ID: 30051651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
    Galadanci NA; Abdullahi SU; Tabari MA; Abubakar S; Belonwu R; Salihu A; Neville K; Kirkham F; Inusa B; Shyr Y; Phillips S; Kassim AA; Jordan LC; Aliyu MH; Covert BV; DeBaun MR
    Pediatr Blood Cancer; 2015 Mar; 62(3):395-401. PubMed ID: 25399822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants.
    Menendez C; Kahigwa E; Hirt R; Vounatsou P; Aponte JJ; Font F; Acosta CJ; Schellenberg DM; Galindo CM; Kimario J; Urassa H; Brabin B; Smith TA; Kitua AY; Tanner M; Alonso PL
    Lancet; 1997 Sep; 350(9081):844-50. PubMed ID: 9310602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective use of hydroxyurea for sickle cell anemia in low-resource countries.
    Power-Hays A; Ware RE
    Curr Opin Hematol; 2020 May; 27(3):172-180. PubMed ID: 32205588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa.
    Olupot-Olupot P; Connon R; Kiguli S; Opoka RO; Alaroker F; Uyoga S; Nakuya M; Okiror W; Nteziyaremye J; Ssenyondo T; Nabawanuka E; Kayaga J; Williams Mukisa C; Amorut D; Muhindo R; Frost G; Walsh K; Macharia AW; Gibb DM; Walker AS; George EC; Maitland K; Williams TN
    Am J Hematol; 2022 May; 97(5):527-536. PubMed ID: 35147242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing hydroxyurea therapy for sickle cell anemia.
    Ware RE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():436-43. PubMed ID: 26637755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
    N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
    Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria.
    Abdullahi SU; Gambo S; Murtala HA; Kabir H; Shamsu KA; Gwarzo G; Acra S; Stallings VA; Rodeghier M; DeBaun MR; Klein LJ
    Blood Adv; 2023 Oct; 7(20):6024-6034. PubMed ID: 37428866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
    Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia.
    Rees DC; Kilinc Y; Unal S; Dampier C; Pace BS; Kaya B; Trompeter S; Odame I; Mahlangu J; Unal S; Brent J; Grosse R; Fuh BR; Inusa BPD; Koren A; Leblebisatan G; Levin C; McNamara E; Meiser K; Hom D; Oliver SJ
    Blood; 2022 Apr; 139(17):2642-2652. PubMed ID: 35226723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub-Saharan Africa.
    Segbefia CI; Smart LR; Stuber SE; Amissah-Arthur KN; Dzefi-Tettey K; Ekpale P; Mensah E; Lane AC; Ghunney W; Tagoe LG; Oteng A; Amoako E; Latham TS; Dei-Adomakoh YA; Ware RE
    Br J Haematol; 2024 Dec; 205(6):2470-2480. PubMed ID: 39406687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnesium for treating sickle cell disease.
    Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
    Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnesium for treating sickle cell disease.
    Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011358. PubMed ID: 31498421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.